Key Points
- CEO Martine Rothblatt sold 8,984 UTHR shares on March 12 at an average price of $537.97 for about $4.83 million, reducing her holding by 98.57% to 130 shares (≈$69,936).
- United Therapeutics reported Q4 EPS of $7.70 (vs. $6.78 est.) with revenue of $790.2M, and analysts have raised price targets leaving a consensus "Moderate Buy" with an average target of $548.09.
- The company has a market cap of $23.42B, a PE of 19.15, a 12‑month range of $266.98–$548.12, and roughly 94% institutional ownership.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 516 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $534.99, for a total value of $276,054.84. Following the transaction, the chief executive officer owned 8,414 shares of the company's stock, valued at $4,501,405.86. This represents a 5.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
United Therapeutics Stock Performance
Shares of NASDAQ UTHR opened at $534.30 on Tuesday. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $548.12. The business has a fifty day moving average of $487.57 and a two-hundred day moving average of $463.88. The stock has a market cap of $23.42 billion, a PE ratio of 19.15, a PEG ratio of 1.93 and a beta of 0.84.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.92. The business had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm's quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.19 EPS. Analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Wall Street Analyst Weigh In
UTHR has been the topic of several research analyst reports. Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research note on Thursday, February 26th. TD Cowen boosted their target price on United Therapeutics from $525.00 to $575.00 and gave the stock a "buy" rating in a report on Wednesday, February 25th. Bank of America restated a "neutral" rating on shares of United Therapeutics in a research report on Wednesday, February 25th. Jefferies Financial Group reaffirmed a "buy" rating on shares of United Therapeutics in a report on Monday, March 2nd. Finally, Cantor Fitzgerald lifted their price objective on United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a research report on Thursday, March 12th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $548.09.
Check Out Our Latest Stock Report on UTHR
Hedge Funds Weigh In On United Therapeutics
A number of large investors have recently modified their holdings of the stock. Torren Management LLC bought a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $26,000. Activest Wealth Management raised its position in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 56 shares during the last quarter. Entrust Financial LLC acquired a new position in United Therapeutics during the 4th quarter worth $31,000. Wilmington Savings Fund Society FSB lifted its holdings in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after buying an additional 49 shares in the last quarter. Finally, Harbor Capital Advisors Inc. bought a new position in United Therapeutics in the 4th quarter valued at $48,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
